scholarly journals Implications from a microarray analysis: Solute carrier proteins may be potential targets to combat stemness of breast cancer

2020 ◽  
Author(s):  
Meltem DEMİREL KARS
Keyword(s):  
Breast Cancer ◽  
Microarray Analysis ◽  
Carrier Proteins ◽  
Solute Carrier

scholarly journals Sequence and Chromosomal Assignment of a Novel cDNA Identified by Immunoscreening of a Thyroid Expression Library: Similarity to a Family of Mitochondrial Solute Carrier Proteins

1989 ◽  
Vol 3 (9) ◽  
pp. 1498-1508 ◽  
Author(s):  
Raffaele Zarrilli ◽  
Edward L. Oates ◽  
O. Wesley McBride ◽  
Michael I. Lerman ◽  
John Y. Chan ◽  
...  
Keyword(s):  
Chromosomal Assignment ◽  
Carrier Proteins ◽  
Expression Library ◽  
Solute Carrier

scholarly journals Genes up- and down-regulated by dermcidin in breast cancer: a microarray analysis

2008 ◽  
Vol 7 (3) ◽  
pp. 925-932 ◽  
Author(s):  
D.F. Moreira ◽  
B.E. Strauss ◽  
E. Vannier ◽  
J.E. Belizario
Keyword(s):  
Breast Cancer ◽  
Microarray Analysis

scholarly journals Differential expression of solute carrier family 29 member 4 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Survival Data ◽  
Differentially Expressed Gene ◽  
Normal Breast ◽  
Differentially Expressed ◽  
Solute Carrier Family ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Solute Carrier

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 29 member 4, SLC29A4, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC29A4 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC29A4 in primary tumors of the breast was correlated with overall survival in patients with luminal B subtype cancer and in patients with normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC29A4 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Enrico Girardi ◽  
Gennaro Agrimi ◽  
Ulrich Goldmann ◽  
Giuseppe Fiume ◽  
Sabrina Lindinger ◽  
...  
Keyword(s):  
Mitochondrial Respiration ◽  
Genetic Interaction ◽  
Functional Characterization ◽  
Membrane Transporters ◽  
Genetic Interactions ◽  
Functional Information ◽  
Carrier Proteins ◽  
Mitochondrial Import ◽  
Redox Metabolism ◽  
Solute Carrier

AbstractAbout a thousand genes in the human genome encode for membrane transporters. Among these, several solute carrier proteins (SLCs), representing the largest group of transporters, are still orphan and lack functional characterization. We reasoned that assessing genetic interactions among SLCs may be an efficient way to obtain functional information allowing their deorphanization. Here we describe a network of strong genetic interactions indicating a contribution to mitochondrial respiration and redox metabolism for SLC25A51/MCART1, an uncharacterized member of the SLC25 family of transporters. Through a combination of metabolomics, genomics and genetics approaches, we demonstrate a role for SLC25A51 as enabler of mitochondrial import of NAD, showcasing the potential of genetic interaction-driven functional gene deorphanization.

Microarray analysis discriminates BRCA2 mutation-positive from BRCA1 and sporadic breast cancer patient tumour biopsies

10.1038/14298 ◽  
1999 ◽  
Vol 23 (S3) ◽  
pp. 43-43 ◽  
Author(s):  
David J. Duggan ◽  
Ingrid A. Hedenfalk ◽  
Yidong Chen ◽  
Mike Bittner ◽  
Åke Borg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Microarray Analysis ◽  
Sporadic Breast Cancer ◽  
Brca2 Mutation ◽  
Sporadic Breast Cancer Patient

scholarly journals Microarray analysis of RhoC-transformed mammary epithelial cells suggests molecular mechanisms of inflammatory breast cancer

10.1038/87212 ◽  
2001 ◽  
Vol 27 (S4) ◽  
pp. 73-73
Author(s):  
Sofia Merajver ◽  
Zhi-Fen Wu ◽  
Tammy Chang ◽  
Hamid Mirshahidi ◽  
Paul Meltzer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epithelial Cells ◽  
Microarray Analysis ◽  
Inflammatory Breast Cancer ◽  
Molecular Mechanisms ◽  
Mammary Epithelial Cells ◽  
Mammary Epithelial

scholarly journals Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)

2019 ◽  
Vol 112 (7) ◽  
pp. 737-746 ◽  
Author(s):  
Meenakshi Anurag ◽  
Mayanne Zhu ◽  
Chen Huang ◽  
Suhas Vasaikar ◽  
Junkai Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tissue Microarray ◽  
Microarray Analysis ◽  
Immune Tolerance ◽  
Immune Checkpoint ◽  
Mrna Levels ◽  
Breast Cancers ◽  
Er Positive ◽  
Tissue Microarray Analysis ◽  
Positive Breast Cancer

Abstract Background Unlike estrogen receptor (ER)-negative breast cancer, ER-positive breast cancer outcome is less influenced by lymphocyte content, indicating the presence of immune tolerance mechanisms that may be specific to this disease subset. Methods A supervised analysis of microarray data from the ACOSOG Z1031 (Alliance) neoadjuvant aromatase inhibitor (AI) trial identified upregulated genes in Luminal (Lum) B breast cancers that correlated with AI-resistant tumor proliferation (percentage of Ki67-positive cancer nuclei, Pearson r > 0.4) (33 cases Ki67 > 10% on AI) vs LumB breast cancers that were more AI sensitive (33 cases Ki67 < 10% on AI). Overrepresentation analysis was performed using WebGestalt. All statistical tests were two-sided. Results Thirty candidate genes positively correlated (r ≥ 0.4) with AI-resistant proliferation in LumB and were upregulated greater than twofold. Gene ontologies identified that the targetable immune checkpoint (IC) components IDO1, LAG3, and PD1 were overrepresented resistance candidates (P ≤ .001). High IDO1 mRNA was associated with poor prognosis in LumB disease (Molecular Taxonomy of Breast Cancer International Consortium, hazard ratio = 1.43, 95% confidence interval = 1.04 to 1.98, P = .03). IDO1 also statistically significantly correlated with STAT1 at protein level in LumB disease (Pearson r = 0.74). As a composite immune tolerance signature, expression of IFN-γ/STAT1 pathway components was associated with higher baseline Ki67, lower estrogen, and progesterone receptor mRNA levels and worse disease-specific survival (P = .002). In a tissue microarray analysis, IDO1 was observed in stromal cells and tumor-associated macrophages, with a higher incidence in LumB cases. Furthermore, IDO1 expression was associated with a macrophage mRNA signature (M1 by CIBERSORT Pearson r = 0.62 ) and by tissue microarray analysis. Conclusions Targetable IC components are upregulated in the majority of endocrine therapy–resistant LumB cases. Our findings provide rationale for IC inhibition in poor-outcome ER-positive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document